Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
作者： Laurent Peyrin–Biroulet , Pierre Deltenre , Nicolas de Suray , Julien Branche , William J. Sandborn
DOI: 10.1016/J.CGH.2008.03.014
关键词:
摘要: Background & Aims: We performed a meta-analysis of placebo-controlled trials to evaluate safety and efficacy tumor necrosis factor (TNF) antagonists for Crohn's disease. Methods: searched MEDLINE, Cochrane Library, EMBASE. The primary end points were clinical remission luminal disease fistula closure at ≥2 consecutive visits. Deaths, serious infections, malignancies also analyzed by the methods Peto Der Simonian Laird. Results: Fourteen enrolled 3995 patients. In overall analysis, anti-TNF therapy was effective induction week 4 (mean difference, 11%; 95% confidence interval [CI], 6%–16%; P
cghjournal.org参考文章(35)
B Feagan, F Caenepeel, P Vergauwe, L Stitt, G Van Assche, Martine De Vos, S Van Deventer, H Tuynman, G Dhaens, D Hommes, F Baert, P Rutgeerts, The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial Gastroenterology. ,vol. 130, pp. 108- ,(2006)
Anthony K Akobeng, Mary Zachos, Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease Cochrane Database of Systematic Reviews. ,(2003) , 10.1002/14651858.CD003574.PUB2
Stefan Schreiber, Paul Rutgeerts, Richard N Fedorak, Munaa Khaliq–Kareemi, Michael A Kamm, Michel Boivin, Charles N Bernstein, Michael Staun, Ole Østergaard Thomsen, Alison Innes, CDP870 Crohn’s Disease Study Group, None, A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology. ,vol. 129, pp. 807- 818 ,(2005) , 10.1053/J.GASTRO.2005.06.064
T. A. Winter, J. Wright, S. Ghosh, J. Jahnsen, A. Innes, P. Round, Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Alimentary Pharmacology & Therapeutics. ,vol. 20, pp. 1337- 1346 ,(2004) , 10.1111/J.1365-2036.2004.02285.X
D. G Altman, Confidence intervals for the number needed to treat. BMJ. ,vol. 317, pp. 1309- 1312 ,(1998) , 10.1136/BMJ.317.7168.1309
Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll, Crispin Jenkinson, D.John M. Reynolds, David J. Gavaghan, Henry J. McQuay, Assessing the quality of reports of randomized clinical trials : is blinding necessary? Controlled Clinical Trials. ,vol. 17, pp. 1- 12 ,(1996) , 10.1016/0197-2456(95)00134-4
Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts, Robert Enns, Stephen B. Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D. Kent, Paul F. Pollack, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. ,vol. 132, pp. 52- 65 ,(2007) , 10.1053/J.GASTRO.2006.11.041
William J. Sandborn, Stephen B. Hanauer, Seymour Katz, Michael Safdi, Douglas G. Wolf, Richard D. Baerg, William J. Tremaine, Therese Johnson, Nancy N. Diehl, Alan R. Zinsmeister, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. ,vol. 121, pp. 1088- 1094 ,(2001) , 10.1053/GAST.2001.28674
William J Sandborn, Brian G Feagan, Stephen B Hanauer, Daniel H Present, Lloyd R Sutherland, Michael A Kamm, Douglas C Wolf, Jeffrey P Baker, Christopher Hawkey, Andre Archambault, Charles N Bernstein, Claire Novak, Patricia K Heath, Stephan R Targan, CDP571 Crohn's Disease Study Group, An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial Gastroenterology. ,vol. 120, pp. 1330- 1338 ,(2001) , 10.1053/GAST.2001.24042
Paul Rutgeerts, William J Sandborn, Richard N Fedorak, Daniel Rachmilewitz, Dino Tarabar, Peter Gibson, Ole Haagen Nielsen, Gary Wild, Stefan Schreiber, Claudia Pena Rossi, Monia Zignani, Onercept Study Group, None, Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial Clinical Gastroenterology and Hepatology. ,vol. 4, pp. 888- 893 ,(2006) , 10.1016/J.CGH.2006.04.022